Patricia M. Mcgowan
Dublin, L, Ireland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.
Journal: British journal of cancer
Published: March 15, 2025
The ADAMs family of proteases as targets for the treatment of cancer.
Journal: Cancer biology & therapy
Published: April 27, 2016
Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Journal: International journal of cancer
Published: March 21, 2016
ADAM10: a new player in breast cancer progression?
Journal: British journal of cancer
Published: May 16, 2015
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
Journal: Breast cancer research : BCR
Published: February 14, 2015
p53 as a target for the treatment of cancer.
Journal: Cancer treatment reviews
Published: August 05, 2014
ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis.
Journal: EMBO molecular medicine
Published: December 31, 2013
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
Journal: Oncotarget
Published: September 07, 2013
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
Journal: Cancer biology & therapy
Published: June 14, 2013
ADAM-17: a novel therapeutic target for triple negative breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 13, 2012
Targeted therapy for triple-negative breast cancer: where are we?
Journal: International journal of cancer
Published: January 23, 2012
Last Updated: 09/26/2026